<p>Design Therapeutics, Inc.（納斯達克代碼：DSGN - 獲取免費報告）的股票獲得了目前覆蓋該公司的五家評級機構的共識推薦，評級為 “適度買入”，MarketBeat.com 報道。一位研究分析師對該股票給予了賣出評級，三位分析師給予了買入評級，還有一位分析師給予了強烈買入評級。在過去一年中，更新了對該股票覆蓋的券商的平均一年目標價為 14.00 美元。</p>
<p>多家研究機構最近對 DSGN 進行了評估。加拿大皇家銀行在 11 月 20 日的研究報告中將 Design Therapeutics 的股票評級從 “行業表現” 上調至 “跑贏大盤”，並將其目標價從 6.00 美元提高至 13.00 美元。Leerink Partners 在週三的研究報告中將 Design Therapeutics 的評級從 “持有” 上調至 “強烈買入”。Weiss Ratings 在 10 月 8 日的報告中重申了對 Design Therapeutics 股票的 “賣出（d-）” 評級。Craig Hallum 在週三開始對 Design Therapeutics 進行覆蓋，併為該公司設定了 “買入” 評級和 15.00 美元的目標價。最後，華爾街 Zen 在 11 月 8 日的研究報告中將 Design Therapeutics 的股票評級從 “賣出” 上調至 “持有”。</p>
<p>獲取 <strong>Design Therapeutics</strong> 的提醒：</p>
<p><strong>閲讀我們最新的 DSGN 股票分析</strong></p>
<h2>機構投資者對 Design Therapeutics 的看法</h2>
<p>幾家機構投資者最近增加或減少了對該公司的持股。美國銀行在第二季度將其在 Design Therapeutics 的股份增加了 11.1%。美國銀行目前擁有 24,625 股該公司的股票，價值 83,000 美元，此前在上個季度購買了 2,459 股。拉塞爾投資集團在第三季度將其在 Design Therapeutics 的股份增加了 69.6%。拉塞爾投資集團目前擁有 6,377 股該公司的股票，價值 48,000 美元，此前在上個季度購買了 2,618 股。景順公司在第二季度將其在 Design Therapeutics 的股份增加了 26.8%。景順公司目前擁有 14,364 股該公司的股票，價值 48,000 美元，此前在上個季度購買了 3,033 股。MPM Bioimpact LLC 在第一季度將其在 Design Therapeutics 的股份增加了 0.6%。MPM Bioimpact LLC 目前擁有 562,943 股該公司的股票，價值 2,173,000 美元，此前在上個季度購買了 3,396 股。最後，摩根大通在第三季度將其在 Design Therapeutics 的股份增加了 26.7%。摩根大通目前擁有 23,221 股該公司的股票，價值 175,000 美元，此前在上個季度購買了 4,896 股。對沖基金和其他機構投資者持有該公司 56.64% 的股份。</p>
<h2>Design Therapeutics 股價上漲 9.3%</h2>
<p>週四，DSGN 股票開盤價為 9.77 美元。Design Therapeutics 的 12 個月低點為 2.60 美元，12 個月高點為 10.00 美元。該公司的 50 日移動平均線為 7.14 美元，200 日移動平均線為 5.44 美元。該公司的市值為 5.565 億美元，市盈率為-8.21，貝塔值為 1.63。</p>
<p>Design Therapeutics（納斯達克代碼：DSGN - 獲取免費報告）最近在 11 月 5 日發佈了季度財報。該公司報告的每股收益為（0.30 美元），超過了市場共識預期的（0.34 美元）0.04 美元。研究分析師平均預測，Design Therapeutics 在當前財政年度的每股收益將為-0.91。</p>
<h2>Design Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Design Therapeutics, Inc 是一家生物製藥公司，專注於研究、設計、開發和商業化小分子治療藥物，以治療美國的遺傳疾病。該公司利用其 GeneTAC 平台設計和開發因核苷酸重複擴展引起的遺傳疾病的治療候選藥物。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，而不是 Design Therapeutics</li>
<li>低市盈率成長股：解鎖投資機會</li>
<li>MongoDB 剛剛發佈了超預期的季度財報——但它是否過熱？</li>
<li>什麼是標準普爾 500 指數，它與其他指數有何不同</li>
<li>三隻有望受益於谷歌 AI 突破的股票</li>
<li>如何投資科技股以及值得考慮的頂級科技股</li>
<li>超越 NVIDIA：五隻有望主導 2026 年的半導體股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFNHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFNHTg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Design Therapeutics 嗎？</h2>
<p>在考慮投資 Design Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Design Therapeutics 並不在名單上。</p>
<p>雖然 Design Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
<p>在這裏查看這五隻股票</p>

DSGN

<p>Design Therapeutics, Inc.（納斯達克代碼：DSGN）獲得了五家券商的共識 “適度買入” 評級，平均目標價為 14.00 美元。加拿大皇家銀行將該股票評級上調至 “跑贏大盤”，並將目標價提高至 13.00 美元。機構投資者已調整其持股，摩根大通和美國銀行增加了其持倉。該股票目前交易價格為 9.77 美元，市值為 5.565 億美元。公司報告的季度收益好於預期，每股收益為（0.30 美元）</p>

<p>Shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) have received a consensus recommendation of &#34;Moderate Buy&#34; from the five ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $14.00.</p>
<div class="lb-trans"><p>Design Therapeutics, Inc.（納斯達克代碼：DSGN - 獲取免費報告）的股票獲得了目前覆蓋該公司的五家評級機構的共識推薦，評級為 “適度買入”，MarketBeat.com 報道。一位研究分析師對該股票給予了賣出評級，三位分析師給予了買入評級，還有一位分析師給予了強烈買入評級。在過去一年中，更新了對該股票覆蓋的券商的平均一年目標價為 14.00 美元。</p>
</div><p>A number of research firms recently weighed in on DSGN. Royal Bank Of Canada raised shares of Design Therapeutics from a &#34;sector perform&#34; rating to an &#34;outperform&#34; rating and increased their price objective for the stock from $6.00 to $13.00 in a research report on Thursday, November 20th. Leerink Partnrs upgraded Design Therapeutics from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Wednesday. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Design Therapeutics in a report on Wednesday, October 8th. Craig Hallum started coverage on Design Therapeutics in a report on Wednesday. They set a &#34;buy&#34; rating and a $15.00 target price for the company. Finally, Wall Street Zen upgraded shares of Design Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 8th.</p>
<div class="lb-trans"><p>多家研究機構最近對 DSGN 進行了評估。加拿大皇家銀行在 11 月 20 日的研究報告中將 Design Therapeutics 的股票評級從 “行業表現” 上調至 “跑贏大盤”，並將其目標價從 6.00 美元提高至 13.00 美元。Leerink Partners 在週三的研究報告中將 Design Therapeutics 的評級從 “持有” 上調至 “強烈買入”。Weiss Ratings 在 10 月 8 日的報告中重申了對 Design Therapeutics 股票的 “賣出（d-）” 評級。Craig Hallum 在週三開始對 Design Therapeutics 進行覆蓋，併為該公司設定了 “買入” 評級和 15.00 美元的目標價。最後，華爾街 Zen 在 11 月 8 日的研究報告中將 Design Therapeutics 的股票評級從 “賣出” 上調至 “持有”。</p>
</div><p>Get <strong>Design Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Design Therapeutics</strong> 的提醒：</p>
</div><p><strong>Read Our Latest Stock Analysis on DSGN</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 DSGN 股票分析</strong></p>
</div><h2>Institutional Investors Weigh In On Design Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Design Therapeutics 的看法</h2>
</div><p>Several institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE grew its position in shares of Design Therapeutics by 11.1% in the 2nd quarter. Bank of America Corp DE now owns 24,625 shares of the company's stock valued at $83,000 after buying an additional 2,459 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in Design Therapeutics by 69.6% in the third quarter. Russell Investments Group Ltd. now owns 6,377 shares of the company's stock valued at $48,000 after acquiring an additional 2,618 shares in the last quarter. Invesco Ltd. boosted its stake in Design Therapeutics by 26.8% in the second quarter. Invesco Ltd. now owns 14,364 shares of the company's stock valued at $48,000 after acquiring an additional 3,033 shares in the last quarter. MPM Bioimpact LLC grew its holdings in shares of Design Therapeutics by 0.6% during the first quarter. MPM Bioimpact LLC now owns 562,943 shares of the company's stock worth $2,173,000 after purchasing an additional 3,396 shares during the last quarter. Finally, JPMorgan Chase &amp; Co. increased its position in shares of Design Therapeutics by 26.7% during the third quarter. JPMorgan Chase &amp; Co. now owns 23,221 shares of the company's stock worth $175,000 after purchasing an additional 4,896 shares in the last quarter. Hedge funds and other institutional investors own 56.64% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者最近增加或減少了對該公司的持股。美國銀行在第二季度將其在 Design Therapeutics 的股份增加了 11.1%。美國銀行目前擁有 24,625 股該公司的股票，價值 83,000 美元，此前在上個季度購買了 2,459 股。拉塞爾投資集團在第三季度將其在 Design Therapeutics 的股份增加了 69.6%。拉塞爾投資集團目前擁有 6,377 股該公司的股票，價值 48,000 美元，此前在上個季度購買了 2,618 股。景順公司在第二季度將其在 Design Therapeutics 的股份增加了 26.8%。景順公司目前擁有 14,364 股該公司的股票，價值 48,000 美元，此前在上個季度購買了 3,033 股。MPM Bioimpact LLC 在第一季度將其在 Design Therapeutics 的股份增加了 0.6%。MPM Bioimpact LLC 目前擁有 562,943 股該公司的股票，價值 2,173,000 美元，此前在上個季度購買了 3,396 股。最後，摩根大通在第三季度將其在 Design Therapeutics 的股份增加了 26.7%。摩根大通目前擁有 23,221 股該公司的股票，價值 175,000 美元，此前在上個季度購買了 4,896 股。對沖基金和其他機構投資者持有該公司 56.64% 的股份。</p>
</div><h2>Design Therapeutics Trading Up 9.3%</h2>
<div class="lb-trans"><h2>Design Therapeutics 股價上漲 9.3%</h2>
</div><p>Shares of DSGN stock opened at $9.77 on Thursday. Design Therapeutics has a 12-month low of $2.60 and a 12-month high of $10.00. The business's 50 day moving average is $7.14 and its two-hundred day moving average is $5.44. The company has a market capitalization of $556.50 million, a P/E ratio of -8.21 and a beta of 1.63.</p>
<div class="lb-trans"><p>週四，DSGN 股票開盤價為 9.77 美元。Design Therapeutics 的 12 個月低點為 2.60 美元，12 個月高點為 10.00 美元。該公司的 50 日移動平均線為 7.14 美元，200 日移動平均線為 5.44 美元。該公司的市值為 5.565 億美元，市盈率為-8.21，貝塔值為 1.63。</p>
</div><p>Design Therapeutics (NASDAQ:DSGN - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.04. On average, research analysts predict that Design Therapeutics will post -0.91 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Design Therapeutics（納斯達克代碼：DSGN - 獲取免費報告）最近在 11 月 5 日發佈了季度財報。該公司報告的每股收益為（0.30 美元），超過了市場共識預期的（0.34 美元）0.04 美元。研究分析師平均預測，Design Therapeutics 在當前財政年度的每股收益將為-0.91。</p>
</div><h2>Design Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Design Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.</p>
<div class="lb-trans"><p>Design Therapeutics, Inc 是一家生物製藥公司，專注於研究、設計、開發和商業化小分子治療藥物，以治療美國的遺傳疾病。該公司利用其 GeneTAC 平台設計和開發因核苷酸重複擴展引起的遺傳疾病的治療候選藥物。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Design Therapeutics</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>MongoDB Just Posted a Blowout Quarter—But Is It Too Hot to Touch?</li>
<li>What is the S&amp;P 500 and How It is Distinct from Other Indexes</li>
<li>3 Stocks Poised to Benefit From Google’s AI Breakthough</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，而不是 Design Therapeutics</li>
<li>低市盈率成長股：解鎖投資機會</li>
<li>MongoDB 剛剛發佈了超預期的季度財報——但它是否過熱？</li>
<li>什麼是標準普爾 500 指數，它與其他指數有何不同</li>
<li>三隻有望受益於谷歌 AI 突破的股票</li>
<li>如何投資科技股以及值得考慮的頂級科技股</li>
<li>超越 NVIDIA：五隻有望主導 2026 年的半導體股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFNHTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=DSGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Design Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Design Therapeutics 嗎？</h2>
</div><p>Before you consider Design Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Design Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Design Therapeutics 並不在名單上。</p>
</div><p>While Design Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Design Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Design Therapeutics, Inc.（納斯達克股票代碼：DSGN）被券商給予 “適度買入” 的平均評級